Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Mantel-Cox Log-Rank Test01:19

The Mantel-Cox Log-Rank Test

965
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of...
965
Wilcoxon Rank-Sum Test01:21

Wilcoxon Rank-Sum Test

666
The Wilcoxon rank-sum test, also known as the Mann-Whitney U test, is a nonparametric test used to determine if there is a significant difference between the distributions of two independent samples. This test is designed specifically for two independent populations and has the following key requirements:
666
Quantifying and Rejecting Outliers: The Grubbs Test01:02

Quantifying and Rejecting Outliers: The Grubbs Test

3.4K
Sometimes, a data set can have a recorded numerical observation that greatly  deviates from the rest of the data. Assuming that the data is normally distributed, a statistical method called the Grubbs test can be used to determine whether the observation is truly an outlier.  To perform a two-tailed Grubbs test, first, calculate the absolute difference between the outlier and the mean. Then, calculate the ratio between this difference and the standard deviation of the sample. This...
3.4K
Expected Frequencies in Goodness-of-Fit Tests01:19

Expected Frequencies in Goodness-of-Fit Tests

7.0K
A goodness-of-fit test is conducted to determine whether the observed frequency values are statistically similar to the frequencies expected for the dataset. Suppose the expected frequencies for a dataset are equal such as when predicting the frequency of any number appearing when casting a die. In that case, the expected frequency is the ratio of the total number of observations (n)  to the number of categories (k).
7.0K
Goodness-of-Fit Test01:16

Goodness-of-Fit Test

8.1K
The goodness-of-fit test is a type of hypothesis test which determines whether the data "fits" a particular distribution. For example, one may suspect that some anonymous data may fit a binomial distribution. A chi-square test (meaning the distribution for the hypothesis test is chi-square) can be used to determine if there is a fit. The null and alternative hypotheses may be written in sentences or stated as equations or inequalities. The test statistic for a goodness-of-fit test is given as...
8.1K
Wilcoxon Signed-Ranks Test for Matched Pairs01:09

Wilcoxon Signed-Ranks Test for Matched Pairs

437
The Wilcoxon signed-rank test for matched pairs evaluates the null hypothesis by combining the ranks of differences with their signs. It essentially tests whether the median of the differences in a population of matched pairs is zero. Since the test incorporates more information than the sign test, it generally yields more trustable conclusions. This test also does not require the data to follow a normal distribution, but two conditions must be met for it to be applicable: (1) the data must...
437

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practical considerations when using the covariate-adjusted log-rank test for the analysis of time-to-event endpoints in oncology trials.

Biometrics·2026
Same author

Estimating the Variance of Covariate-Adjusted Estimators of Average Treatment Effects in Clinical Trials With Binary Endpoints.

Pharmaceutical statistics·2025
Same author

Visualizing hypothesis tests in survival analysis under anticipated delayed effects.

Pharmaceutical statistics·2024
Same author

Stratified modestly weighted log-rank tests in settings with an anticipated delayed separation of survival curves.

Biometrical journal. Biometrische Zeitschrift·2023
Same author

Improved group sequential Holm procedures for testing multiple correlated hypotheses over time.

Journal of biopharmaceutical statistics·2021
Same author

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.

European journal of heart failure·2021
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same journal

Will the Pharmaceutical Industry Need Statisticians in an AI World?

Pharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Jan 8, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.5K

Robust Modestly Weighted Log-Rank Tests.

Dominic Magirr1, Fredrik Öhrn2

  • 1Advanced Quantitative Sciences, Novartis, Basel, Switzerland.

Pharmaceutical Statistics
|December 18, 2025
PubMed
Summary
This summary is machine-generated.

A novel statistical test enhances survival analysis in immuno-oncology by combining log-rank and weighted methods. This approach improves power for delayed treatment effects while maintaining robustness in clinical trials.

Keywords:
assurancedelayed effectmultiplicityweighted log‐rank tests

More Related Videos

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

470
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K

Related Experiment Videos

Last Updated: Jan 8, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.5K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

470
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K

Area of Science:

  • Biostatistics
  • Clinical Trial Methodology
  • Immunotherapy Research

Background:

  • The log-rank test is standard for immuno-oncology trials but struggles with non-proportional hazards.
  • Checkpoint inhibitors can lead to delayed or non-proportional survival benefits, challenging traditional analysis.
  • Existing weighted log-rank tests have limitations, including potential counterintuitive results or reduced power in specific scenarios.

Purpose of the Study:

  • To develop a novel statistical test for immuno-oncology confirmatory trials.
  • To enhance the power and robustness of survival analysis, especially with non-proportional hazards.
  • To provide a reliable primary analysis method for checkpoint inhibitor studies.

Main Methods:

  • Proposed a new test statistic integrating standard log-rank, modestly weighted log-rank, and MaxCombo test principles.
  • The novel statistic maximizes the standard log-rank and a modestly weighted log-rank statistic.
  • Evaluated the test's performance using simulation studies and a real-world case study.

Main Results:

  • The proposed test demonstrates efficiency and robustness in simulation and case studies.
  • It maintains statistical power in scenarios with delayed separation of survival curves.
  • It minimizes power loss compared to the standard log-rank test in worst-case scenarios.

Conclusions:

  • The novel integrated test statistic offers a robust alternative for primary analysis in immuno-oncology.
  • It effectively addresses the challenges posed by non-proportional hazards and delayed treatment effects.
  • This approach has the potential to improve the reliability of clinical trial results in immuno-oncology.